Observations on the resistance of Fpstein-Barr virus DNA synthesis to hydroxyurea

Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide

A previous study had established a relationship between the major polypeptide of the Epstein-Barr Virus (EBV)-induced restricted (R) component of the early antigen (EA) complex and the large subunit of ribonucleotide reductase. This association was confirmed in this study by the observation that a monoclonal antibody prepared against the 85-kDa R component reacted in immunoblotting with the protein product (molecular weight approximately 93 kDa) encoded by the Xbal fragment of the B-95-8 strain of EBV. This fragment encodes for both the small and large subunits of this virus-induced enzyme. This size of the reactive protein indicated that it was the large subunit. Direct evidence that the 85-kDa EA-R component was associated with the viral-induced ribonucleotide reductase was provided by enzyme inhibition studies. Two monoclonal antibodies prepared against the tertiary structure of the 85-kDa EA-R antigen significantly inhibited the in vitro activity of the viral-specified enzyme but had no effect on ribonucleotide reductase activity derived from two different cellular preparations. A monoclonal antibody prepared against the denatured form of this antigen was ineffective in neutralizing the virus-specific ribonucleotide reductase as were antibodies to different EBV polypeptides. These results therefore conclusively demonstrate that the 85-kDa EA-R polypeptide is associated with the large subunit of this viral-specified enzyme and further suggest that the active site of the enzyme is associated with the tertiary structure of the large subunit.

Effects of DNA synthesis inhibitors on early antigen expression following primary infection or superinfection by Epstein-Barr virus

Seven lymphoid cell lines previously characterized with respect to their resident Epstein-Barr virus (EBV) genome content were infected or superinfected with concentrated EBV from supernatant of the P3HR-1 cell line. Immunofluorescence assays were conducted on smears 48 hours after infection, using human sera containing antibodies to EBV early antigen (EA). Two EBV nuclear antigen (EBNA) negative cell lines containing no detectable resident EBV DNA and five EBNA positive cell lines containing EBV genomes were tested. The cell lines did not spontaneously express EBV EA (i.e., they were non-producers). All cell lines responded to infection or superinfection with EBV by expressing EA. Treatment of the cell lines with arabinosylcytosine (Ara-C) 10 micrograms/ml, at the time of infection resulted in significant decreases in the number of cells expressing detectable EA after drug treatment in all cell lines (72 +/- 5 percent inhibition of EA expression). Experiments were also conducted with hydroxyurea (HU) and phosphonoacetic acid (PAA). It was found that treatment with HU (100 micrograms/ml) inhibited EA production in cell lines containing EBV genome copies by 81 percent as compared to the superinfected cultures receiving no drug. In primary infection of EBNA negative cell lines, HU had minimal effects. PAA (100 micrograms/ml), on the other hand, had very little effect on EA expression following superinfection of cell lines harboring the EBV genome, but reduced the EA expression after primary infection of EBNA negative cell lines by 70 to 80 percent. All drugs were used at concentrations having little effect on RNA and protein synthesis. However, HU and Ara-C significantly reduced DNA synthesis and cell division in the treated cultures.

Epstein-Barr virus polypeptides: effect of inhibition of viral DNA replication on their synthesis

After Epstein-Barr virus superinfection of the human lymphoblastoid cell line Raji, a Burkitt lymphoma-derived line that contains Epstein-Barr virus genomes in an episomal form, at least 40 polypeptides could be resolved by polyacrylamide gel electrophoresis. Eleven of the 40 polypeptides were immunoprecipitable by early antigen+/viral capsid antigen+ antiserum. The polypeptides could be divided into six classes, immediate-early, early, intermediate, late, very late, and persistent, depending upon the time of synthesis. Ten of the 40 polypeptides appeared to preexist before superinfection and persisted despite general cessation of host protein synthesis; none of the persistent proteins was immunoprecipitated by the Epstein-Barr virus antibody-containing serum. When viral DNA replication was blocked by a variety of inhibitors of DNA synthesis, a number of different patterns of polypeptide synthesis could be detected. The synthesis of six polypeptides was blocked by the most virus-specific inhibitors, acyclovir and phosphonoacetic acid. Additionally, in the presence of 1-beta-D-arabinofuranosylcytosine, 1-beta-D-arabinofuranosyladenine, and methotrexate, seven polypeptides showed oversynthesis.

Hydroxyurea

Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis. It is anti-mitotic and cytotoxic depending on the concentration used, the duration of exposure, and the sensitivity of the organism. In most cells HU is active mainly in the S-phase of the cycle and because of the easy reversibility of its action it has been used as a synchronising agent in cell cultures with some success. There is conflicting evidence about the ability of HU to act as an inhibitor of the natural DNA repair mechanisms in cells exposed to radiation or alkylating agents. HU has, however, been shown to induce chromosome damage in a number of organisms including man. It is clearly teratogenic in mammals and can cross the placental barrier at least in rats and the golden hamster, but it is believed to have only a limited mutagenic activity. Studies involving a direct comparison of the action of HU with other compounds suggest that the = C--NHOH moiety is responsible for its biological activity.